Cargando…

Temperature Upshifts in Mammalian Cell Culture: A Suitable Strategy for Biosimilar Monoclonal Antibodies?

Temperature downshifts are the gold standard when setting up control strategies for mammalian cell culture processes. These shifts are performed to prolong production phases and attain heightened levels of productivity. For the development of biosimilars, however, the bottleneck is in achieving a pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marschall, Lukas, Gottimukkala, Chitti Babu, Kayal, Biswajit, Veeraraghavan, Veerabhadra Madurai, Mandal, Samir Kumar, Bandyopadhyay, Suman, Herwig, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603922/ https://www.ncbi.nlm.nih.gov/pubmed/37892879 http://dx.doi.org/10.3390/bioengineering10101149

Ejemplares similares

An Aversive Response to Osmotic Upshift in Caenorhabditis elegans
por: Yu, Jingyi, et al.
Publicado: (2017)

Physiochemical Modeling of Vesicle Dynamics upon Osmotic Upshift
por: Gabba, Matteo, et al.
Publicado: (2020)

Has the COVID-19 Pandemic Caused Upshifting in Colorectal Cancer Stage?
por: Lim, Ji Ha, et al.
Publicado: (2021)

Relativistic electron mirrors from nanoscale foils for coherent frequency upshift to the extreme ultraviolet
por: Kiefer, D., et al.
Publicado: (2013)

Lateral orbitofrontal neurons acquire responses to upshifted, downshifted, or blocked cues during unblocking
por: Lopatina, Nina, et al.
Publicado: (2015)

Relativistic frequency upshift to the extreme ultraviolet regime using self-induced oscillatory flying mirrors
por: Kim, I Jong, et al.
Publicado: (2012)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Therapeutic Monoclonal Antibodies and Emergence of Their Biosimilars
por: Jeddi-Tehrani, Mahmood
Publicado: (2018)

Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
por: Doevendans, Erik, et al.
Publicado: (2019)

Subnanometric Ru clusters with upshifted D band center improve performance for alkaline hydrogen evolution reaction
por: Hu, Qi, et al.
Publicado: (2022)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Virulence genes of Rickettsia rickettsii are differentially modulated by either temperature upshift or blood-feeding in tick midgut and salivary glands
por: Galletti, Maria Fernanda B. M., et al.
Publicado: (2016)

P-37 Has the COVID-19 pandemic lead to an upshift in emergency presentation and stage migration of colorectal cancer in Uruguay?
por: Fontes, S., et al.
Publicado: (2022)

Expert perspectives on biosimilar monoclonal antibodies in breast cancer
por: Cortés, J., et al.
Publicado: (2014)

Biosimilar monoclonal antibodies in China: A patent review
por: Liu, Jia-Wei, et al.
Publicado: (2022)

EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies
por: Francescon, Sara, et al.
Publicado: (2018)

Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges
por: Chapman, Kathryn, et al.
Publicado: (2016)

Biosimilar structural comparability assessment by NMR: from small proteins to monoclonal antibodies
por: Japelj, Boštjan, et al.
Publicado: (2016)

An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
por: Moorkens, Evelien, et al.
Publicado: (2020)

Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective
por: Kurki, Pekka, et al.
Publicado: (2021)

Pelvis reconstruction by proximal femur upshifting and total hip arthroplasty after radical resection of an adolescent patient pelvic Ewing's sarcoma, a case report, and literature review
por: Mahran, Mohamed A., et al.
Publicado: (2023)

In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin
por: Akbarzadeh-Sharbaf, Soudabeh, et al.
Publicado: (2012)

Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies
por: Reijers, Joannes A. A., et al.
Publicado: (2016)

Biosimilars
por: Martin, Miguel
Publicado: (2018)

Generation and Validation of Monoclonal Antibodies Suitable for Detecting and Monitoring Parvovirus Infections
por: Tessmer, Claudia, et al.
Publicado: (2022)

Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2016)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Tunable recombinant protein expression in E. coli: promoter systems and genetic constraints
por: Marschall, Lukas, et al.
Publicado: (2016)

Tunable recombinant protein expression in E. coli: enabler for continuous processing?
por: Marschall, Lukas, et al.
Publicado: (2016)

Oncology biosimilars: New developments and future directions
por: Bachu, Rinda Devi, et al.
Publicado: (2022)

Epitope Characterization of an Aromatase Monoclonal Antibody Suitable for the Assessment of Intratumoral Aromatase Activity
por: Hong, Yanyan, et al.
Publicado: (2009)

Comparison of Three Complementary Analytical Techniques for the Evaluation of the Biosimilar Comparability of a Monoclonal Antibody and an Fc-Fusion Protein
por: Demelenne, Alice, et al.
Publicado: (2021)

Biosimilars in dermatology
por: Mazur, Małgorzata, et al.
Publicado: (2015)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Biosimilars in oncology
por: Tabernero, Josep
Publicado: (2018)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
por: Uifălean, Alina, et al.
Publicado: (2018)

Decision tree for selection of suitable cultivation parameters for mammalian cell culture processes
por: Pörtner, Ralf, et al.
Publicado: (2015)

Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab
por: Muñoz-Villegas, Patricia, et al.
Publicado: (2021)

Real world safety of CT-P10 (anti-CD 20 monoclonal antibodies biosimilar) in rheumatic and autoimmune diseases
por: Katchamart, Wanruchada, et al.
Publicado: (2022)

Maximizing the benefits of using biosimilars in Egypt
por: Fasseeh, Ahmad Nader, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9qlmkbppme2nteoe5762ktma1f